Richard Law
Stock Analyst at Goldman Sachs
(3.30)
# 1,063
Out of 5,093 analysts
70
Total ratings
39.39%
Success rate
25.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Buy | $18 → $26 | $26.58 | -2.18% | 6 | Nov 21, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $120 → $135 | $105.09 | +28.46% | 1 | Nov 18, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $29.76 | -2.55% | 2 | Oct 30, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Neutral | $35 → $40 | $47.90 | -16.49% | 1 | Sep 26, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $36.73 | +41.57% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $31.80 | -5.66% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $14.55 | +463.57% | 4 | Aug 6, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $6.20 | -51.61% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.36 | +286.90% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $28.09 | +10.36% | 3 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $30 | $37.28 | -19.53% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $73 | $96.36 | -24.24% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $16.99 | -35.26% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $26.48 | +77.49% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $57.04 | +10.45% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $86.88 | -57.41% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $9.30 | +717.20% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.44 | +473.77% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $13.10 | +365.65% | 4 | May 8, 2023 |
Olema Pharmaceuticals
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $26
Current: $26.58
Upside: -2.18%
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $120 → $135
Current: $105.09
Upside: +28.46%
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $29.76
Upside: -2.55%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $47.90
Upside: -16.49%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $36.73
Upside: +41.57%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $31.80
Upside: -5.66%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $14.55
Upside: +463.57%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $6.20
Upside: -51.61%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.36
Upside: +286.90%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $28.09
Upside: +10.36%
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $37.28
Upside: -19.53%
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $96.36
Upside: -24.24%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $16.99
Upside: -35.26%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $26.48
Upside: +77.49%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $57.04
Upside: +10.45%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $86.88
Upside: -57.41%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $9.30
Upside: +717.20%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.44
Upside: +473.77%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $13.10
Upside: +365.65%